🔎 Trials Near Me

መነሻ › ኖን-ሆጅኪን ሊምፎማ › Oregon

በOregon ለኖን-ሆጅኪን ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች

ለኖን-ሆጅኪን ሊምፎማ የሚደረጉ 15 ጥናቶች በOregon ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በOregon ውስጥ ያሉ ከተሞች

Official study text (English)

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • Oregon Health and Sciences University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06343311

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Providence Health & Services, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT02693535

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Oregon Health & Science University (OHSU), Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07226843

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06526793

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  • Oncology Associates of Oregon, P.C, Eugene
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06806033

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ13 እስከ 90 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06533579

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Oregon Health and Science University Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦገስ 2026 · NCT06116110

DALY II USA/ MB-CART2019.1 for DLBCL

  • Oregon Health and Science University Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT04792489

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Oregon Health & Science University/Doernbecher Children's Hospital, Portland
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Providence Neurological Specialties West, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ኤፕሪ 2026 · NCT03328078

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Kaiser Permanente Northwest, Portland
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06418204

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Oregon Health and Science University - Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ፌብሩ 2026 · NCT05544019

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

  • Local Institution - 0016, Portland
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ22 ጃንዩ 2026 · NCT06357754

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Portland
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • Oregon Health & Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2025 · NCT05780034

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።